<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Cardiovasc. Med.</journal-id>
<journal-title>Frontiers in Cardiovascular Medicine</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Cardiovasc. Med.</abbrev-journal-title>
<issn pub-type="epub">2297-055X</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fcvm.2021.778038</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Cardiovascular Medicine</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>A Non-Linear Association of Triglyceride Glycemic Index With Cardiovascular and All-Cause Mortality Among Patients With Hypertension</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Zhou</surname> <given-names>Dan</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="author-notes" rid="fn002"><sup>&#x02020;</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/1356572/overview"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Liu</surname> <given-names>Xiao-cong</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="author-notes" rid="fn002"><sup>&#x02020;</sup></xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Kenneth</surname> <given-names>Lo</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Huang</surname> <given-names>Yu-qing</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Feng</surname> <given-names>Ying-qing</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="corresp" rid="c001"><sup>&#x0002A;</sup></xref>
</contrib>
</contrib-group>
<aff id="aff1"><sup>1</sup><institution>Department of Cardiology, Guangdong Cardiovascular Institute, Guangdong Provincial People&#x00027;s Hospital, Guangdong Academy of Medical Sciences</institution>, <addr-line>Guangzhou</addr-line>, <country>China</country></aff>
<aff id="aff2"><sup>2</sup><institution>Department of Epidemiology, Centre for Global Cardio-Metabolic Health, Brown University</institution>, <addr-line>Providence, RI</addr-line>, <country>United States</country></aff>
<aff id="aff3"><sup>3</sup><institution>Department of Applied Biology and Chemical Technology, The Hong Kong Polytechnic University, Hong Kong</institution>, <addr-line>Hong Kong SAR</addr-line>, <country>China</country></aff>
<author-notes>
<fn fn-type="edited-by"><p>Edited by: Modar Kassan, University of Tennessee Health Science Center (UTHSC), United States</p></fn>
<fn fn-type="edited-by"><p>Reviewed by: Yang Peng, The University of Queensland, Australia; Masahide Hamaguchi, Kyoto Prefectural University of Medicine, Japan</p></fn>
<corresp id="c001">&#x0002A;Correspondence: Ying-qing Feng <email>1250780250&#x00040;qq.com</email></corresp>
<fn fn-type="other" id="fn001"><p>This article was submitted to Hypertension, a section of the journal Frontiers in Cardiovascular Medicine</p></fn>
<fn fn-type="equal" id="fn002"><p>&#x02020;These authors have contributed equally to this work</p></fn></author-notes>
<pub-date pub-type="epub">
<day>27</day>
<month>01</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="collection">
<year>2021</year>
</pub-date>
<volume>8</volume>
<elocation-id>778038</elocation-id>
<history>
<date date-type="received">
<day>16</day>
<month>09</month>
<year>2021</year>
</date>
<date date-type="accepted">
<day>27</day>
<month>12</month>
<year>2021</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#x000A9; 2022 Zhou, Liu, Kenneth, Huang and Feng.</copyright-statement>
<copyright-year>2022</copyright-year>
<copyright-holder>Zhou, Liu, Kenneth, Huang and Feng</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/"><p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p></license> </permissions>
<abstract>
<sec>
<title>Background</title>
<p>To investigate the association between insulin resistance (IR), quantified by triglyceride glycemic index (TyG index), cardiovascular mortality (CVM), and all-cause mortality (ACM) in hypertension patients.</p>
</sec>
<sec>
<title>Methods</title>
<p>We included 8,554 patients with hypertension aged &#x02265;18 years old from the 1999&#x02013;2014 National Health and Nutrition Examination Surveys (NHANES). The status of CVM and ACM of participants were followed through December 31, 2015. Cox proportional hazards models and Kaplan-Meier survival curves were used to evaluate the relationship between TyG index, CVM, and ACM.</p>
</sec>
<sec>
<title>Results</title>
<p>During a median of 82 months follow-up, 1,882 mortality cases had occurred, 434 of which were due to cardiovascular disease. The patients with hypertension with TyG &#x02265; 10 were older, had a higher chance of being smokers, were obese, had higher blood pressure, and had risk or had cardiovascular disease. In Cox proportional hazards models, compared with the patients with TyG &#x0003C;8, those with TyG &#x02265; 10 had 56% increased risk for ACM. On the other hand, no significant difference for CVM between the four groups were observed. In the restricted cubic spline regression models, the relationship between TyG index and ACM was non-linear. Subgroup analysis showed non-linear relationship between TyG index and ACM in elderly patients aged &#x02265;60 years. The cut-off value of TyG for ACM was 9.45, and those with higher or lower than 9.45 had more risk of ACM. When TyG index was more than 9.52, the risk for CVM would increase among the whole group. Kaplan-Meier survival curves showed patients with TyG &#x02265; 10 had higher risk of ACM and CVM (Log rank <italic>P</italic> &#x0003C; 0.05).</p>
</sec>
<sec>
<title>Conclusions</title>
<p>We demonstrated that the association between ACM and TyG index in elderly patients with hypertension aged &#x02265;60 years was non-linear. However, TyG index was only more than 9.52, hence, the risk for CVM would increase among the whole hypertension group.</p>
</sec></abstract>
<kwd-group>
<kwd>insulin resistance</kwd>
<kwd>triglyceride-glucose index</kwd>
<kwd>hypertension</kwd>
<kwd>all-cause mortality</kwd>
<kwd>cardiovascular mortality</kwd>
</kwd-group>
<counts>
<fig-count count="3"/>
<table-count count="4"/>
<equation-count count="0"/>
<ref-count count="26"/>
<page-count count="9"/>
<word-count count="5669"/>
</counts>
</article-meta>
</front>
<body>
<sec id="s1">
<title>Background</title>
<p>Hypertension is a primary risk factor for cardiovascular disease and all-cause mortality (ACM) (<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B2">2</xref>). Careful risk factor assessment plays an important role in hypertension patients. The metabolic effects of insulin resistance (IR), including hyperglycemia and dyslipidemia, appear to interact synergistically with increased blood pressure to cause vascular and kidney injury (<xref ref-type="bibr" rid="B3">3</xref>). IR is proposed to be important contributors to hypertension-caused organ damage, arterial stiffness (<xref ref-type="bibr" rid="B4">4</xref>), and left ventricular diastolic dysfunction (<xref ref-type="bibr" rid="B5">5</xref>) due to hypertension. Hence, higher IR is a risk factor for hypertension patients.</p>
<p>At present, Homeostatic model assessment IR (HOMA-IR), a method for assessing &#x003B2;-cell function and IR, is frequently applied, but its high cost and inconvenience make it difficult to use in large cohort study. Therefore, there has been no large cohort study examinate the prognosis value of IR in hypertension group.</p>
<p>Triglyceride-Glucose index (TyG index), first published by South American authors, showed a good correlation with the insulin clamp technique and HOMA-IR index. The TyG index, described to be a simple, convenient, and low-cost method, is of research interest in many countries in Asia and can be used to screen for IR in the Asian hypertensive community (<xref ref-type="bibr" rid="B6">6</xref>). Despite this, there is no evidence between TyG index and prognosis value in North America hypertensive community. Therefore, we conducted a retrospective cohort study to certify the relationship of cardiovascular mortality (CVM) and ACM in hypertension patients.</p>
</sec>
<sec sec-type="methods" id="s2">
<title>Methods</title>
<sec>
<title>Study Population</title>
<p>The National Health and Nutrition Examination Surveys (NHANES), sponsored by the Centers for Disease Control and Prevention, is designed to assess the health status of US citizens. Data for analyses were taken from the NHANES 1999&#x02013;2014 with a total of 82,091 participants. In our analysis, we included people aged &#x02265; 18 years old. Subjects without blood lipid data, fasting blood glucose data, follow-up data, or baseline without hypertension were excluded. After applying the criteria, we enrolled 8,554 participants for final analysis (<xref ref-type="fig" rid="F1">Figure 1</xref>). The survival status of participants was followed up to December 31, 2015. The NHANES study protocol was approved by the Institutional Review Board of the Centers for Disease Control and Prevention. Informed consent was signed by all participants.</p>
<fig id="F1" position="float">
<label>Figure 1</label>
<caption><p>Study cohort.</p></caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fcvm-08-778038-g0001.tif"/>
</fig>
</sec>
<sec>
<title>Data Collection</title>
<p>Questionnaires were collected at baseline to acquire demographic information (age, gender, race, marital status, and education level), smoking status, personal medical history (cardiovascular diseases and diabetes), and medication history (antihypertensive drugs, hypoglycemic agents, lipid-lowering drug, and antiplatelet drugs).</p>
<p>Physical assessments were performed to examine height, weight, systolic blood pressure (SBP), and diastolic blood pressure (DBP). Blood samples were collected on an empty stomach in the morning and after 8 h. Total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), fasting blood glucose (FBG), and estimated glomerular filtration rate (eGFR) were also collected. Body mass index (BMI) was calculated using weight (kg) divided by the square of height (m<sup>2</sup>). Hypertension was defined as having an SBP &#x02265; 140 or/and DBP &#x02265; 90 mmHg, is confirmed to be taking antihypertensive medications, or has a self-reported history of hypertension (<xref ref-type="bibr" rid="B7">7</xref>). Diabetes was defined as having an FBG &#x02265; 126 mg/dl, having a self-reported hemoglobin A1c(HbA1C) &#x02265; 6.5%, or using hypoglycemic drug (<xref ref-type="bibr" rid="B8">8</xref>). TyG index was calculated by ln [fasting triglycerides (mg/dl) <sup>&#x0002A;</sup>fasting glucose (mg/dl)/2] (<xref ref-type="bibr" rid="B9">9</xref>). eGFR was computed using Modification of Diet in Renal Disease (MDRD) formula (<xref ref-type="bibr" rid="B10">10</xref>).</p>
</sec>
<sec>
<title>Clinical Outcome</title>
<p>All-cause mortality refer to death from any cause, cardiovascular disease, or cerebrovascular disease until December 31, 2015 were the primary outcomes. Mortality data were extracted from the 1999&#x02013;2014 NHANES public-use linked mortality files. We examined the time from enrollment (date of interview) to mortality for censoring. The International Classification of Diseases, Tenth Revision codes (I00-I09, I11, I13, I20-I51) were used to define cardiovascular deaths. Any participant who was not matched with any death records was considered to be alive throughout the follow-up period.</p>
</sec>
<sec>
<title>Statistical Analysis</title>
<p>Continuous variables were expressed as mean &#x000B1; standard deviation for normally distributed variables or median (interquartile range) if the data were not normally distributed. Categorical variables were presented as number (n) and percentage (%). The one-way ANOVA, Kruskal&#x02013;Wallis <italic>H</italic>-test or chi-square tests were used to assess differences according to baseline TyG index (TyG &#x0003C;8, 8 &#x02264; TyG &#x0003C;9, 9 &#x02264; TyG &#x0003C;10, TyG &#x02265; 10) in groups. Multivariable Cox regression analysis were used to estimate adjusted hazard ratio (HR) and 95% CI for mortality according to baseline TyG index in groups. Model I adjust for none. Model II adjust for age, gender, and race. Age, gender, race, smoking, marital status, education level, BMI, SBP, eGFR, TC, HDL-C, comorbidities (cardiovascular disease and diabetes), and medicine use (antihypertensive drugs, hypoglycemic agents, lipid-lowering drugs, and antiplatelet drugs) were included in Model III. We initially performed survival analysis using standardized Kaplan&#x02013;Meier curves and Log rank test. The association between TyG index, ACM, and CVM was then examined by multivariate adjusted Cox restricted cubic spline regression models and used a generalized additive model to explore the non-linear relationship between TyG index and mortality. If non-linear relationships were identified, we used two-piecewise linear regression models to elucidate how the associations differed by the threshold point. The threshold value was estimated by trying all possible value and choosing the threshold point with highest likelihood. Finally, we conducted subgroup analyses, including age (&#x0003C;65 or &#x02265;65 years), gender (male or female), race (white or non-white), and BMI (&#x0003C;25 or &#x02265;25 kg/m<sup>2</sup>). <italic>P</italic> &#x0003C; 0.05 was considered statistically significant. R version 3.3.2 (R Foundation for Statistical Computing, Vienna, Austria) was used for all statistical analyses.</p>
</sec>
</sec>
<sec sec-type="results" id="s3">
<title>Results</title>
<sec>
<title>Baseline Characteristics</title>
<p>The baseline characteristics of the analytical cohort according to TyG index in groups were showed in <xref ref-type="table" rid="T1">Table 1</xref>. In total, 8,554 patients (49.29% men) were included in this analysis with mean age of 60.12 &#x000B1; 16.07 years. Of these, 4,309 (50.37%) participants were white, 4,632 (54.91%) married, 5,716 (67.70%) received high school or above education, and 4,178 (49.40%) never smoked. The patients with hypertension in group of TyG &#x02265; 10 were older, were more likely to be smokers, were obese, had higher blood pressure, and had higher risk or had cardiovascular disease. In addition, the proportion of participants with diabetes and cardiovascular disease was 30.33 and 19.36%, respectively. During a median follow up of 82 months, 1,882 cases of death have occurred, 434 of which were due to cardiovascular disease. All baseline variables differed significantly among the TyG index in groups (all <italic>p</italic> &#x0003C; 0.05).</p>
<table-wrap position="float" id="T1">
<label>Table 1</label>
<caption><p>Demographic and clinical characteristics according to triglyceride-glucose index level.</p></caption>
<table frame="hsides" rules="groups">
<thead><tr>
<th/>
<th valign="top" align="center"><bold>Total</bold></th>
<th valign="top" align="center"><bold>TyG &#x0003C;8</bold></th>
<th valign="top" align="center"><bold>8 &#x02264;T yG &#x0003C;9</bold></th>
<th valign="top" align="center"><bold>9 &#x02264;TyG &#x0003C;10</bold></th>
<th valign="top" align="center"><bold>TyG &#x02265;10</bold></th>
<th valign="top" align="center"><bold><italic>p</italic></bold></th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="left">Number</td>
<td valign="top" align="center">8,554</td>
<td valign="top" align="center">690</td>
<td valign="top" align="center">4,655</td>
<td valign="top" align="center">2,743</td>
<td valign="top" align="center">466</td>
<td/>
</tr>
<tr>
<td valign="top" align="left">Age, years</td>
<td valign="top" align="center">60.12 &#x000B1; 16.07</td>
<td valign="top" align="center">54.13 &#x000B1; 18.33</td>
<td valign="top" align="center">60.70 &#x000B1; 16.32</td>
<td valign="top" align="center">60.92 &#x000B1; 15.01</td>
<td valign="top" align="center">58.50 &#x000B1; 13.96</td>
<td valign="top" align="center">&#x0003C;0.001</td>
</tr>
<tr>
<td valign="top" align="left"><bold>Gender, n (%)</bold></td>
<td/>
<td/>
<td/>
<td/>
<td/>
<td valign="top" align="center">&#x0003C;0.001</td>
</tr>
<tr>
<td valign="top" align="left">Male</td>
<td valign="top" align="center">4,216 (49.29)</td>
<td valign="top" align="center">327 (47.39)</td>
<td valign="top" align="center">2,203 (47.33)</td>
<td valign="top" align="center">1,412 (51.48)</td>
<td valign="top" align="center">274 (58.80)</td>
<td/>
</tr>
<tr>
<td valign="top" align="left">Female</td>
<td valign="top" align="center">4,338 (50.71)</td>
<td valign="top" align="center">363 (52.61)</td>
<td valign="top" align="center">2,452 (52.67)</td>
<td valign="top" align="center">1,331 (48.52)</td>
<td valign="top" align="center">192 (41.20)</td>
<td/>
</tr>
<tr>
<td valign="top" align="left"><bold>Race, n (%)</bold></td>
<td/>
<td/>
<td/>
<td/>
<td/>
<td valign="top" align="center">&#x0003C;0.001</td>
</tr>
<tr>
<td valign="top" align="left">Non-white</td>
<td valign="top" align="center">4,245 (49.63)</td>
<td valign="top" align="center">432 (62.61)</td>
<td valign="top" align="center">2,335 (50.16)</td>
<td valign="top" align="center">1,238 (45.13)</td>
<td valign="top" align="center">240 (51.50)</td>
<td/>
</tr>
<tr>
<td valign="top" align="left">White</td>
<td valign="top" align="center">4,309 (50.37)</td>
<td valign="top" align="center">258 (37.39)</td>
<td valign="top" align="center">2,320 (49.84)</td>
<td valign="top" align="center">1,505 (54.87)</td>
<td valign="top" align="center">226 (48.50)</td>
<td/>
</tr>
<tr>
<td valign="top" align="left"><bold>Marital status, n (%)</bold></td>
<td/>
<td/>
<td/>
<td/>
<td/>
<td valign="top" align="center">&#x0003C;0.001</td>
</tr>
<tr>
<td valign="top" align="left">Married</td>
<td valign="top" align="center">4,632 (54.91)</td>
<td valign="top" align="center">329 (48.53)</td>
<td valign="top" align="center">2,493 (54.31)</td>
<td valign="top" align="center">1,552 (57.29)</td>
<td valign="top" align="center">258 (56.33)</td>
<td/>
</tr>
<tr>
<td valign="top" align="left">Other</td>
<td valign="top" align="center">3,803 (45.09)</td>
<td valign="top" align="center">349 (51.47)</td>
<td valign="top" align="center">2,097 (45.69)</td>
<td valign="top" align="center">1,157 (42.71)</td>
<td valign="top" align="center">200 (43.67)</td>
<td/>
</tr>
<tr>
<td valign="top" align="left"><bold>Education level, n (%)</bold></td>
<td/>
<td/>
<td/>
<td/>
<td/>
<td valign="top" align="center">&#x0003C;0.001</td>
</tr>
<tr>
<td valign="top" align="left">Less than high school</td>
<td valign="top" align="center">2,727 (32.30)</td>
<td valign="top" align="center">173 (26.13)</td>
<td valign="top" align="center">1,412 (30.70)</td>
<td valign="top" align="center">945 (34.77)</td>
<td valign="top" align="center">197 (42.55)</td>
<td/>
</tr>
<tr>
<td valign="top" align="left">High school or above</td>
<td valign="top" align="center">5,716 (67.70)</td>
<td valign="top" align="center">489 (73.87)</td>
<td valign="top" align="center">3,188 (69.30)</td>
<td valign="top" align="center">1,773 (65.23)</td>
<td valign="top" align="center">266 (57.45)</td>
<td/>
</tr>
<tr>
<td valign="top" align="left"><bold>Smoking, n (%)</bold></td>
<td/>
<td/>
<td/>
<td/>
<td/>
<td valign="top" align="center">&#x0003C;0.001</td>
</tr>
<tr>
<td valign="top" align="left">No</td>
<td valign="top" align="center">4,178 (49.40)</td>
<td valign="top" align="center">365 (54.80)</td>
<td valign="top" align="center">2,366 (51.38)</td>
<td valign="top" align="center">1,251 (45.93)</td>
<td valign="top" align="center">196 (42.33)</td>
<td/>
</tr>
<tr>
<td valign="top" align="left">Yes</td>
<td valign="top" align="center">4,280 (50.60)</td>
<td valign="top" align="center">301 (45.20)</td>
<td valign="top" align="center">2,239 (48.62)</td>
<td valign="top" align="center">1,473 (54.07)</td>
<td valign="top" align="center">267 (57.67)</td>
<td/>
</tr>
<tr>
<td valign="top" align="left">Body mass index, kg/m<sup>2</sup></td>
<td valign="top" align="center">30.31 &#x000B1; 7.09</td>
<td valign="top" align="center">28.11 &#x000B1; 7.30</td>
<td valign="top" align="center">29.76 &#x000B1; 7.26</td>
<td valign="top" align="center">31.49 &#x000B1; 6.51</td>
<td valign="top" align="center">32.15 &#x000B1; 6.80</td>
<td valign="top" align="center">&#x0003C;0.001</td>
</tr>
<tr>
<td valign="top" align="left">Systolic blood pressure, mmHg</td>
<td valign="top" align="center">135.62 &#x000B1; 21.35</td>
<td valign="top" align="center">133.21 &#x000B1; 20.58</td>
<td valign="top" align="center">135.11 &#x000B1; 21.62</td>
<td valign="top" align="center">136.53 &#x000B1; 20.96</td>
<td valign="top" align="center">138.89 &#x000B1; 21.55</td>
<td valign="top" align="center">&#x0003C;0.001</td>
</tr>
<tr>
<td valign="top" align="left">Diastolic blood pressure, mmHg</td>
<td valign="top" align="center">71.00 &#x000B1; 16.07</td>
<td valign="top" align="center">71.07 &#x000B1; 16.05</td>
<td valign="top" align="center">70.44 &#x000B1; 16.21</td>
<td valign="top" align="center">71.79 &#x000B1; 15.69</td>
<td valign="top" align="center">71.93 &#x000B1; 16.69</td>
<td valign="top" align="center">0.004</td>
</tr>
<tr>
<td valign="top" align="left">eGFR, mg/min/1.73m<sup>2</sup></td>
<td valign="top" align="center">79.31 &#x000B1; 26.93</td>
<td valign="top" align="center">86.21 &#x000B1; 27.81</td>
<td valign="top" align="center">79.29 &#x000B1; 26.98</td>
<td valign="top" align="center">77.24 &#x000B1; 25.85</td>
<td valign="top" align="center">81.55 &#x000B1; 29.48</td>
<td valign="top" align="center">&#x0003C;0.001</td>
</tr>
<tr>
<td valign="top" align="left">Total cholesterol, mg/dL</td>
<td valign="top" align="center">197.68 &#x000B1; 43.43</td>
<td valign="top" align="center">179.68 &#x000B1; 39.45</td>
<td valign="top" align="center">193.14 &#x000B1; 40.25</td>
<td valign="top" align="center">204.94 &#x000B1; 43.47</td>
<td valign="top" align="center">226.94 &#x000B1; 56.40</td>
<td valign="top" align="center">&#x0003C;0.001</td>
</tr>
<tr>
<td valign="top" align="left">HDL cholesterol, mg/dL</td>
<td valign="top" align="center">52.87 &#x000B1; 16.31</td>
<td valign="top" align="center">66.46 &#x000B1; 19.88</td>
<td valign="top" align="center">56.03 &#x000B1; 15.75</td>
<td valign="top" align="center">46.36 &#x000B1; 12.26</td>
<td valign="top" align="center">39.46 &#x000B1; 11.65</td>
<td valign="top" align="center">&#x0003C;0.001</td>
</tr>
<tr>
<td valign="top" align="left">LDL cholesterol, mg/dL</td>
<td valign="top" align="center">115.31 &#x000B1; 36.57</td>
<td valign="top" align="center">102.64 &#x000B1; 32.30</td>
<td valign="top" align="center">116.05 &#x000B1; 35.35</td>
<td valign="top" align="center">117.83 &#x000B1; 38.74</td>
<td valign="top" align="center">109.09 &#x000B1; 38.95</td>
<td valign="top" align="center">&#x0003C;0.001</td>
</tr>
<tr>
<td valign="top" align="left">Triglycerides, mg/dL</td>
<td valign="top" align="center">150.58 &#x000B1; 117.66</td>
<td valign="top" align="center">52.23 &#x000B1; 11.80</td>
<td valign="top" align="center">104.85 &#x000B1; 28.96</td>
<td valign="top" align="center">203.81 &#x000B1; 65.30</td>
<td valign="top" align="center">439.76 &#x000B1; 291.68</td>
<td valign="top" align="center">&#x0003C;0.001</td>
</tr>
<tr>
<td valign="top" align="left">Fasting blood glucose, mg/dL</td>
<td valign="top" align="center">115.87 &#x000B1; 42.86</td>
<td valign="top" align="center">92.76 &#x000B1; 12.14</td>
<td valign="top" align="center">104.34 &#x000B1; 18.47</td>
<td valign="top" align="center">125.30 &#x000B1; 40.63</td>
<td valign="top" align="center">209.87 &#x000B1; 94.41</td>
<td valign="top" align="center">&#x0003C;0.001</td>
</tr>
<tr>
<td valign="top" align="left">TyG index</td>
<td valign="top" align="center">8.86 &#x000B1; 0.68</td>
<td valign="top" align="center">7.76 &#x000B1; 0.21</td>
<td valign="top" align="center">8.56 &#x000B1; 0.27</td>
<td valign="top" align="center">9.37 &#x000B1; 0.26</td>
<td valign="top" align="center">10.51 &#x000B1; 0.47</td>
<td valign="top" align="center">&#x0003C;0.001</td>
</tr>
<tr>
<td valign="top" align="left"><bold>Comorbidities, n (%)</bold></td>
<td/>
<td/>
<td/>
<td/>
<td/>
<td/>
</tr>
<tr>
<td valign="top" align="left">diabetes</td>
<td/>
<td/>
<td/>
<td/>
<td/>
<td valign="top" align="center">&#x0003C;0.001</td>
</tr>
<tr>
<td valign="top" align="left">No</td>
<td valign="top" align="center">5,958 (69.67)</td>
<td valign="top" align="center">613 (88.84)</td>
<td valign="top" align="center">3,695 (79.39)</td>
<td valign="top" align="center">1,560 (56.89)</td>
<td valign="top" align="center">90 (19.31)</td>
<td/>
</tr>
<tr>
<td valign="top" align="left">Yes</td>
<td valign="top" align="center">2,594 (30.33)</td>
<td valign="top" align="center">77 (11.16)</td>
<td valign="top" align="center">959 (20.61)</td>
<td valign="top" align="center">1,182 (43.11)</td>
<td valign="top" align="center">376 (80.69)</td>
<td/>
</tr>
<tr>
<td valign="top" align="left"><bold>Cardiovascular disease</bold></td>
<td/>
<td/>
<td/>
<td/>
<td/>
<td valign="top" align="center">&#x0003C;0.001</td>
</tr>
<tr>
<td valign="top" align="left">No</td>
<td valign="top" align="center">6,821 (80.64)</td>
<td valign="top" align="center">570 (85.84)</td>
<td valign="top" align="center">3,776 (81.98)</td>
<td valign="top" align="center">2,124 (77.92)</td>
<td valign="top" align="center">351 (75.81)</td>
<td/>
</tr>
<tr>
<td valign="top" align="left">Yes</td>
<td valign="top" align="center">1,638 (19.36)</td>
<td valign="top" align="center">94 (14.16)</td>
<td valign="top" align="center">830 (18.02)</td>
<td valign="top" align="center">602 (22.08)</td>
<td valign="top" align="center">112 (24.19)</td>
<td/>
</tr>
<tr>
<td valign="top" align="left"><bold>Treatment, n (%)</bold></td>
<td/>
<td/>
<td/>
<td/>
<td/>
<td/>
</tr>
<tr>
<td valign="top" align="left"><bold>Antihypertensive drugs</bold></td>
<td/>
<td/>
<td/>
<td/>
<td/>
<td valign="top" align="center">&#x0003C;0.001</td>
</tr>
<tr>
<td valign="top" align="left">No</td>
<td valign="top" align="center">3,254 (38.04)</td>
<td valign="top" align="center">333 (48.26)</td>
<td valign="top" align="center">1,854 (39.83)</td>
<td valign="top" align="center">919 (33.50)</td>
<td valign="top" align="center">148 (31.76)</td>
<td/>
</tr>
<tr>
<td valign="top" align="left">Yes</td>
<td valign="top" align="center">5,300 (61.96)</td>
<td valign="top" align="center">357 (51.74)</td>
<td valign="top" align="center">2,801 (60.17)</td>
<td valign="top" align="center">1,824 (66.50)</td>
<td valign="top" align="center">318 (68.24)</td>
<td/>
</tr>
<tr>
<td valign="top" align="left"><bold>Hypoglycemic agents</bold></td>
<td/>
<td/>
<td/>
<td/>
<td/>
<td valign="top" align="center">&#x0003C;0.001</td>
</tr>
<tr>
<td valign="top" align="left">No</td>
<td valign="top" align="center">7,115 (83.18)</td>
<td valign="top" align="center">647 (93.77)</td>
<td valign="top" align="center">4,149 (89.13)</td>
<td valign="top" align="center">2,089 (76.16)</td>
<td valign="top" align="center">230 (49.36)</td>
<td/>
</tr>
<tr>
<td valign="top" align="left">Yes</td>
<td valign="top" align="center">1,439 (16.82)</td>
<td valign="top" align="center">43 (6.23)</td>
<td valign="top" align="center">506 (10.87)</td>
<td valign="top" align="center">654 (23.84)</td>
<td valign="top" align="center">236 (50.64)</td>
<td/>
</tr>
<tr>
<td valign="top" align="left"><bold>Lipid-lowering drugs</bold></td>
<td/>
<td/>
<td/>
<td/>
<td/>
<td valign="top" align="center">&#x0003C;0.001</td>
</tr>
<tr>
<td valign="top" align="left">No</td>
<td valign="top" align="center">6,309 (73.75)</td>
<td valign="top" align="center">569 (82.46)</td>
<td valign="top" align="center">3,498 (75.15)</td>
<td valign="top" align="center">1,936 (70.58)</td>
<td valign="top" align="center">306 (65.67)</td>
<td/>
</tr>
<tr>
<td valign="top" align="left">Yes</td>
<td valign="top" align="center">2,245 (26.25)</td>
<td valign="top" align="center">121 (17.54)</td>
<td valign="top" align="center">1,157 (24.85)</td>
<td valign="top" align="center">807 (29.42)</td>
<td valign="top" align="center">160 (34.33)</td>
<td/>
</tr>
<tr>
<td valign="top" align="left"><bold>Antiplatelet drugs</bold></td>
<td/>
<td/>
<td/>
<td/>
<td/>
<td valign="top" align="center">0.024</td>
</tr>
<tr>
<td valign="top" align="left">No</td>
<td valign="top" align="center">8,185 (95.69)</td>
<td valign="top" align="center">666 (96.52)</td>
<td valign="top" align="center">4,476 (96.15)</td>
<td valign="top" align="center">2,600 (94.79)</td>
<td valign="top" align="center">443 (95.06)</td>
<td/>
</tr>
<tr>
<td valign="top" align="left">Yes</td>
<td valign="top" align="center">369 (4.31)</td>
<td valign="top" align="center">24 (3.48)</td>
<td valign="top" align="center">179 (3.85)</td>
<td valign="top" align="center">143 (5.21)</td>
<td valign="top" align="center">23 (4.94)</td>
<td/>
</tr>
<tr>
<td valign="top" align="left"><bold>Outcomes, n (%)</bold></td>
<td/>
<td/>
<td/>
<td/>
<td/>
<td/>
</tr>
<tr>
<td valign="top" align="left"><bold>Cardiovascular disease mortality</bold></td>
<td/>
<td/>
<td/>
<td/>
<td/>
<td valign="top" align="center">&#x0003C;0.001</td>
</tr>
<tr>
<td valign="top" align="left">No</td>
<td valign="top" align="center">8,120 (94.93)</td>
<td valign="top" align="center">659 (95.51)</td>
<td valign="top" align="center">4,445 (95.49)</td>
<td valign="top" align="center">2,595 (94.60)</td>
<td valign="top" align="center">421 (90.34)</td>
<td/>
</tr>
<tr>
<td valign="top" align="left">Yes</td>
<td valign="top" align="center">434 (5.07)</td>
<td valign="top" align="center">31 (4.49)</td>
<td valign="top" align="center">210 (4.51)</td>
<td valign="top" align="center">148 (5.40)</td>
<td valign="top" align="center">45 (9.66)</td>
<td/>
</tr>
<tr>
<td valign="top" align="left"><bold>All-cause mortality</bold></td>
<td/>
<td/>
<td/>
<td/>
<td/>
<td valign="top" align="center">&#x0003C;0.001</td>
</tr>
<tr>
<td valign="top" align="left">No</td>
<td valign="top" align="center">6,672 (78.00)</td>
<td valign="top" align="center">582 (84.35)</td>
<td valign="top" align="center">3,650 (78.41)</td>
<td valign="top" align="center">2,125 (77.47)</td>
<td valign="top" align="center">315 (67.60)</td>
<td/>
</tr>
<tr>
<td valign="top" align="left">Yes</td>
<td valign="top" align="center">1,882 (22.00)</td>
<td valign="top" align="center">108 (15.65)</td>
<td valign="top" align="center">1,005 (21.59)</td>
<td valign="top" align="center">618 (22.53)</td>
<td valign="top" align="center">151 (32.40)</td>
<td/>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p><italic>Q, quintiles; n, number; HDL, high density lipoprotein; LDL, low density lipoprotein; TyG, Triglyceride-glucose.</italic></p> 
<p><italic>Values are mean &#x000B1; standardized differences or n (%)</italic>.</p>
</table-wrap-foot>
</table-wrap>
</sec>
<sec>
<title>Hazard Ratios (HRs) of TyG Index for ACM and CVM Risk</title>
<p><xref ref-type="table" rid="T2">Table 2</xref> reveals the estimated HRs and CIs of TyG index in relation to ACM and CVM. In the Model III, compared with the lowest group of TyG index (TyG &#x0003C;8), the HRs for ACM from other groups (8 &#x02264; TyG &#x0003C;9, 9 &#x02264; TyG &#x0003C;10, TyG &#x02265; 10) in the fully adjusted model were 0.90 (0.72 to &#x02212;1.13, <italic>p</italic> = 0.36), 0.85 (0.66&#x02013;1.10, <italic>p</italic> = 0.21), and 1.56 (1.14&#x02013;2.15, <italic>p</italic> &#x0003C; 0.05), respectively (<italic>P</italic> for trend = 0.09).</p>
<table-wrap position="float" id="T2">
<label>Table 2</label>
<caption><p>Multivariate Cox regression analysis of triglyceride-glucose index with cause-specific mortality.</p></caption>
<table frame="hsides" rules="groups">
<thead><tr>
<th/>
<th valign="top" align="center"><bold>Event rate/1,000 person-years</bold></th>
<th valign="top" align="center"><bold>Model I</bold></th>
<th valign="top" align="center"><bold>Model II</bold></th>
<th valign="top" align="center"><bold>Model III</bold></th>
</tr>
<tr>
<th/>
<th/>
<th valign="top" align="center"><bold>HR (95%CI), <italic>p</italic> value</bold></th>
<th valign="top" align="center"><bold>HR (95%CI), <italic>p</italic> value</bold></th>
<th valign="top" align="center"><bold>HR (95%CI), <italic>p</italic> value</bold></th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="left" colspan="5"><bold>All-cause mortality</bold></td>
</tr>
<tr>
<td valign="top" align="left" colspan="5"><bold>TyG index group</bold></td>
</tr>
<tr>
<td valign="top" align="left">TyG &#x0003C;8</td>
<td valign="top" align="center">24.07</td>
<td valign="top" align="center">1.0</td>
<td valign="top" align="center">1.0</td>
<td valign="top" align="center">1.0</td>
</tr>
<tr>
<td valign="top" align="left">8 &#x02264; TyG &#x0003C;9</td>
<td valign="top" align="center">29.16</td>
<td valign="top" align="center">1.19 (0.98, 1.45), 0.0841</td>
<td valign="top" align="center">0.84 (0.69, 1.02), 0.0794</td>
<td valign="top" align="center">0.90 (0.72, 1.13), 0.3626</td>
</tr>
<tr>
<td valign="top" align="left">9 &#x02264; TyG &#x0003C;10</td>
<td valign="top" align="center">29.02</td>
<td valign="top" align="center">1.18 (0.96, 1.45), 0.1153</td>
<td valign="top" align="center">0.84 (0.68, 1.03), 0.0923</td>
<td valign="top" align="center">0.85 (0.66, 1.10), 0.2127</td>
</tr>
<tr>
<td valign="top" align="left">TyG &#x02265; 10</td>
<td valign="top" align="center">43.45</td>
<td valign="top" align="center">1.78 (1.39, 2.28), &#x0003C;0.0001</td>
<td valign="top" align="center">1.56 (1.22, 1.99), 0.0005</td>
<td valign="top" align="center">1.56 (1.14, 2.15), 0.0061</td>
</tr>
<tr>
<td valign="top" align="left">P for trend</td>
<td/>
<td valign="top" align="center">&#x0003C;0.001</td>
<td valign="top" align="center">0.002</td>
<td valign="top" align="center">0.099</td>
</tr>
<tr>
<td valign="top" align="left" colspan="5"><bold>Cardiovascular mortality</bold></td>
</tr>
<tr>
<td valign="top" align="left" colspan="5"><bold>TyG index group</bold></td>
</tr>
<tr>
<td valign="top" align="left">TyG &#x0003C;8</td>
<td valign="top" align="center">6.91</td>
<td valign="top" align="center">1.0</td>
<td valign="top" align="center">1.0</td>
<td valign="top" align="center">1.0</td>
</tr>
<tr>
<td valign="top" align="left">8 &#x02264; TyG &#x0003C;9</td>
<td valign="top" align="center">6.09</td>
<td valign="top" align="center">0.87 (0.60, 1.27), 0.4776</td>
<td valign="top" align="center">0.62 (0.42, 0.90), 0.0125</td>
<td valign="top" align="center">0.55 (0.36, 0.82), 0.0039</td>
</tr>
<tr>
<td valign="top" align="left">9 &#x02264; TyG &#x0003C;10</td>
<td valign="top" align="center">6.95</td>
<td valign="top" align="center">0.99 (0.67, 1.46), 0.9543</td>
<td valign="top" align="center">0.72 (0.49, 1.07), 0.1011</td>
<td valign="top" align="center">0.53 (0.33, 0.86), 0.0092</td>
</tr>
<tr>
<td valign="top" align="left">TyG &#x02265; 10</td>
<td valign="top" align="center">12.95</td>
<td valign="top" align="center">1.84 (1.17, 2.91), 0.0088</td>
<td valign="top" align="center">1.69 (1.07, 2.67), 0.0252</td>
<td valign="top" align="center">1.23 (0.67, 2.25), 0.5044</td>
</tr>
<tr>
<td valign="top" align="left">P for trend</td>
<td/>
<td valign="top" align="center">0.002</td>
<td valign="top" align="center">0.002</td>
<td valign="top" align="center">0.438</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p><italic>TyG, triglyceride-glucose; HR, hazard ratio; CI, confidence interval; Q, quintiles.</italic></p> 
<p><italic>Model I adjust for none.</italic></p>
<p><italic>Model II adjust for age, gender, and race.</italic></p>
<p><italic>Model III adjust for age, gender, race, smoking, marital status, education level, body mass index, systolic blood pressure, estimated glomerular filtration rate, total cholesterol, high density lipoprotein cholesterol, comorbidities (cardiovascular disease and diabetes), and medicine use (antihypertensive drugs, hypoglycemic agents, lipid-lowering drugs, and antiplatelet drugs)</italic>.</p>
</table-wrap-foot>
</table-wrap>
<p>Population with TyG &#x02265; 10 showed a 56% increased risk of ACM compared with those TyG &#x0003C;8. After an adjustment for confounders, the HRs and CIs for CVM from the three groups (8 &#x02264; TyG &#x0003C;9, 9 &#x02264; TyG &#x0003C;10, TyG &#x02265; 10) were 0.55 (0.36, 0.82), 0.53 (0.33, 0.86), and 1.23 (0.67, 2.25), respectively (<italic>P</italic> for trend = 0.43). After excluding type 2 diabetes mellitus or cardiovascular disease in the baseline, in <xref ref-type="supplementary-material" rid="SM1">Supplementary Table 1</xref>, we found that when comparing with the lowest group of TyG index (TyG &#x0003C;8), the HRs for ACM from TyG &#x02265; 10 in the fully adjusted model were 2.05 (1.04, 4.04) (<italic>p</italic> = 0.03). However, it was not associated with any change in the risk of CVM.</p>
<p>In the restricted cubic spline regression models with full adjustment for confounders, the relationships between TyG index, ACM (<xref ref-type="fig" rid="F2">Figure 2A</xref>), and CVM (<xref ref-type="fig" rid="F2">Figure 2B</xref>) were both non-linear in participants with hypertension. The results of two piecewise linear regression model are demonstrated in <xref ref-type="table" rid="T3">Table 3</xref>. The relationship between TyG index and ACM was non-linear. Subgroup analysis (<xref ref-type="table" rid="T4">Table 4</xref>) showed non-linear relationship between TyG index and ACM in elderly patients with aged &#x02265;60 years. The cut-off value of TyG for ACM was 9.45. Values higher or lower than 9.45 had more risk of ACM. When TyG index was more than 9.52, the risk for CVM would increase among the whole group.</p>
<fig id="F2" position="float">
<label>Figure 2</label>
<caption><p>Spline analyses of all-cause <bold>(A)</bold> and cardiovascular <bold>(B)</bold> mortality by TyG index in the overall cohort and the probability distribution histogram is represented in the background (spline analyses were adjusted for age, gender, race, smoking, marital status, education level, body mass index, systolic blood pressure, estimated glomerular filtration rate, total cholesterol, high density lipoprotein cholesterol, cardiovascular disease, diabetes, antihypertensive drugs, hypoglycemic agents, lipid-lowering drugs, and antiplatelet drugs).</p></caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fcvm-08-778038-g0002.tif"/>
</fig>
<table-wrap position="float" id="T3">
<label>Table 3</label>
<caption><p>The results of two-piecewise linear regression model between triglyceride-glucose index and cause-specific mortality.</p></caption>
<table frame="hsides" rules="groups">
<thead><tr>
<th/>
<th valign="top" align="center"><bold>All-cause mortality</bold></th>
<th valign="top" align="center"><bold>Cardiovascular disease mortality</bold></th>
</tr>
<tr>
<th/>
<th valign="top" align="center"><bold>HR (95% CI), <italic>p</italic> value</bold></th>
<th valign="top" align="center"><bold>HR (95% CI), <italic>p</italic> value</bold></th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="left">Cutoff value</td>
<td valign="top" align="center">9.45</td>
<td valign="top" align="center">9.52</td>
</tr>
<tr>
<td valign="top" align="left">&#x0003C; Cut-off value</td>
<td valign="top" align="center">0.87 (0.76, 0.99), 0.0329</td>
<td valign="top" align="center">0.81 (0.62, 1.06), 0.1277</td>
</tr>
<tr>
<td valign="top" align="left">&#x02265; Cut-off value</td>
<td valign="top" align="center">1.73 (1.44, 2.09), &#x0003C;0.0001</td>
<td valign="top" align="center">2.85 (2.05, 3.98), &#x0003C;0.0001</td>
</tr>
<tr>
<td valign="top" align="left"><italic>p</italic> for log likelihood ratio test</td>
<td valign="top" align="center">&#x0003C;0.001</td>
<td valign="top" align="center">&#x0003C;0.001</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p><italic>TyG, triglyceride-glucose; HR, hazard ratio; CI, confidence interval.</italic></p> 
<p><italic>The two-piecewise linear regression model were adjusted for age, gender, race, smoking, marital status, education level, body mass index, systolic blood pressure, estimated glomerular filtration rate, total cholesterol, high density lipoprotein cholesterol, comorbidities (cardiovascular disease and diabetes), and medicine use (antihypertensive drugs, hypoglycemic agents, lipid-lowering drugs, and antiplatelet drugs)</italic>.</p>
</table-wrap-foot>
</table-wrap>
<table-wrap position="float" id="T4">
<label>Table 4</label>
<caption><p>Subgroups analysis.</p></caption>
<table frame="hsides" rules="groups">
<thead><tr>
<th/>
<th valign="top" align="center"><bold>N</bold></th>
<th valign="top" align="center" colspan="2"><bold>All-cause mortality</bold></th>
<th valign="top" align="center"><bold>P for log likelihood ratio test</bold></th>
<th valign="top" align="center" colspan="2"><bold>Cardiovascular disease mortality</bold></th>
<th valign="top" align="center"><bold>P for log likelihood ratio test</bold></th>
</tr>
<tr>
<th/>
<th/>
<th valign="top" align="center" colspan="2" style="border-bottom: thin solid #000000;"><bold>HR (95% CI)</bold>, <italic><bold>p</bold></italic> <bold>value</bold></th>
<th/>
<th valign="top" align="center" colspan="2" style="border-bottom: thin solid #000000;"><bold>HR (95% CI)</bold>, <italic><bold>p</bold></italic> <bold>value</bold></th>
<th/>
</tr>
<tr>
<th valign="top" align="left"><bold>Cutoff value, mmol/L</bold></th>
<th/>
<th valign="top" align="center"><bold> &#x0003C;9.45</bold></th>
<th valign="top" align="center"><bold>&#x02265;9.45</bold></th>
<th/>
<th valign="top" align="center"><bold> &#x0003C;9.52</bold></th>
<th valign="top" align="center"><bold>&#x02265;9.52</bold></th>
<th/>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="left"><bold>Age</bold></td>
<td/>
<td/>
<td/>
<td/>
<td/>
<td/>
<td/>
</tr>
<tr>
<td valign="top" align="left">&#x02265;65</td>
<td valign="top" align="center">3,442</td>
<td valign="top" align="center">0.81 (0.70, 0.95), 0.0080</td>
<td valign="top" align="center">1.48 (1.14, 1.93), 0.0032</td>
<td valign="top" align="center">&#x0003C;0.001</td>
<td valign="top" align="center">0.79 (0.58, 1.08), 0.1364</td>
<td valign="top" align="center">2.36 (1.43, 3.90), 0.0008</td>
<td valign="top" align="center">0.001</td>
</tr>
<tr>
<td valign="top" align="left">&#x0003C;65</td>
<td valign="top" align="center">4,402</td>
<td valign="top" align="center">1.08 (0.83, 1.41), 0.5575</td>
<td valign="top" align="center">1.59 (1.20, 2.10), 0.0011</td>
<td valign="top" align="center">0.071</td>
<td valign="top" align="center">0.86 (0.47, 1.55), 0.6134</td>
<td valign="top" align="center">2.34 (1.42, 3.87), 0.0009</td>
<td valign="top" align="center">0.022</td>
</tr>
<tr>
<td valign="top" align="left"><bold>Gender</bold></td>
<td/>
<td/>
<td/>
<td/>
<td/>
<td/>
<td/>
</tr>
<tr>
<td valign="top" align="left">Male</td>
<td valign="top" align="center">3,889</td>
<td valign="top" align="center">0.86 (0.72, 1.03), 0.0975</td>
<td valign="top" align="center">1.78 (1.40, 2.27), &#x0003C;0.0001</td>
<td valign="top" align="center">&#x0003C;0.001</td>
<td valign="top" align="center">0.92 (0.65, 1.30), 0.6382</td>
<td valign="top" align="center">3.18 (2.12, 4.78), &#x0003C;0.0001</td>
<td valign="top" align="center">&#x0003C;0.001</td>
</tr>
<tr>
<td valign="top" align="left">Female</td>
<td valign="top" align="center">3,955</td>
<td valign="top" align="center">0.86 (0.70, 1.05), 0.1439</td>
<td valign="top" align="center">1.68 (1.25, 2.24), 0.0005</td>
<td valign="top" align="center">0.001</td>
<td valign="top" align="center">0.72 (0.46, 1.13), 0.1541</td>
<td valign="top" align="center">2.23 (1.16, 4.27), 0.0158</td>
<td valign="top" align="center">0.015</td>
</tr>
<tr>
<td valign="top" align="left"><bold>Race</bold></td>
<td/>
<td/>
<td/>
<td/>
<td/>
<td/>
<td/>
</tr>
<tr>
<td valign="top" align="left">Non-white</td>
<td valign="top" align="center">3,847</td>
<td valign="top" align="center">0.83 (0.67, 1.02), 0.0757</td>
<td valign="top" align="center">1.76 (1.35, 2.28), &#x0003C;0.0001</td>
<td valign="top" align="center">&#x0003C;0.001</td>
<td valign="top" align="center">0.71 (0.47, 1.08), 0.1114</td>
<td valign="top" align="center">3.58 (2.30, 5.57), &#x0003C;0.0001</td>
<td valign="top" align="center">&#x0003C;0.001</td>
</tr>
<tr>
<td valign="top" align="left">White</td>
<td valign="top" align="center">3,997</td>
<td valign="top" align="center">0.91 (0.76, 1.08), 0.2892</td>
<td valign="top" align="center">1.63 (1.25, 2.13), 0.0003</td>
<td valign="top" align="center">0.001</td>
<td valign="top" align="center">0.88 (0.61, 1.26) 0.4722</td>
<td valign="top" align="center">2.09 (1.21, 3.62), 0.0087</td>
<td valign="top" align="center">0.020</td>
</tr>
<tr>
<td valign="top" align="left"><bold>Body mass index, kg/m</bold><sup><bold>2</bold></sup></td>
<td/>
<td/>
<td/>
<td/>
<td/>
<td/>
<td/>
</tr>
<tr>
<td valign="top" align="left">&#x0003C;25</td>
<td valign="top" align="center">1,683</td>
<td valign="top" align="center">0.91 (0.71, 1.18), 0.4867</td>
<td valign="top" align="center">3.08 (1.98, 4.79), &#x0003C;0.0001</td>
<td valign="top" align="center">&#x0003C;0.001</td>
<td valign="top" align="center">0.82 (0.49, 1.37), 0.4400</td>
<td valign="top" align="center">4.72 (2.29, 9.71), &#x0003C;0.0001</td>
<td valign="top" align="center">&#x0003C;0.001</td>
</tr>
<tr>
<td valign="top" align="left">&#x02265;25</td>
<td valign="top" align="center">6,161</td>
<td valign="top" align="center">0.85 (0.73, 1.00), 0.0477</td>
<td valign="top" align="center">1.56 (1.26, 1.92), &#x0003C;0.0001</td>
<td valign="top" align="center">&#x0003C;0.001</td>
<td valign="top" align="center">0.79 (0.57, 1.09) 0.1511</td>
<td valign="top" align="center">2.58 (1.74, 3.80), &#x0003C;0.0001</td>
<td valign="top" align="center">&#x0003C;0.001</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p><italic>TyG, triglyceride-glucose; CI, confidence interval.</italic></p> 
<p><italic>When analyzing a subgroup variable, age, gender, race, smoking, body mass index, systolic blood pressure, estimated glomerular filtration rate, total cholesterol, high density lipoprotein cholesterol, comorbidities (cardiovascular disease, diabetes, and hypertension), and medicine use (antihypertensive drugs, hypoglycemic agents, lipid-lowering drugs, and antiplatelet drugs) were all adjusted except the variable itself</italic>.</p>
</table-wrap-foot>
</table-wrap>
<p>As showed in Kaplan-Meier survival curves (<xref ref-type="fig" rid="F3">Figure 3</xref>), hypertension patients with TyG &#x02265; 10 had significantly higher ACM (<xref ref-type="fig" rid="F3">Figure 3A</xref>) and CVM (<xref ref-type="fig" rid="F3">Figure 3B</xref>) in the following life (log rank <italic>p</italic> &#x0003C; 0.05).</p>
<fig id="F3" position="float">
<label>Figure 3</label>
<caption><p>Kaplan-Meier survival curve for all-cause <bold>(A)</bold> and cardiovascular <bold>(B)</bold> mortality by TyG index.</p></caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fcvm-08-778038-g0003.tif"/>
</fig>
</sec>
<sec>
<title>Subgroup Analyses</title>
<p><xref ref-type="table" rid="T4">Table 4</xref> has explored the relationship between TyG index, ACM, and CVM as stratified by gender, age, BMI, and race. Only for age &#x02265; 60 years old patients, the association was significant different between TyG index &#x0003C;9.45 or &#x02265;9.45. When index &#x02265;9.45, risk increased by 48% at every 1 SD increase of TyG index. When index &#x0003C;9.45, risk increased by 19% at every 1 SD decrease of TyG index. Other subgroups only showed a higher TyG index, more than the cut-off value, would present higher risk for ACM and CVM. When TyG index was less than the cut-off value, it showed no difference.</p>
</sec>
</sec>
<sec sec-type="discussion" id="s4">
<title>Discussion</title>
<p>In this retrospective study, we, for the first time, revealed association between IR (TyG index), ACM, and CVM among patients with hypertension in a large cohort study. We demonstrated that the association was non-linear between ACM and TyG index in elderly patient with aged &#x02265;60 years old. But for CVM, only when TyG index was more than 9.52 will the risk for CVM increase among the whole hypertension group.</p>
<p>We also demonstrated the association was non-linear between ACM and TyG index in elderly with aged &#x02265;60 years old. When TyG index &#x02265;9.45, the risk of ACM increased by 48% at every 1 SD increase of TyG index. In contrast, for TyG index &#x0003C;9.45, the risk of ACM increased by 19% as the TyG index decreased by 1 SD. TyG index, a composite indicator based on TG level and FBG value, was shown to be used as a surrogate marker of IR (<xref ref-type="bibr" rid="B9">9</xref>, <xref ref-type="bibr" rid="B11">11</xref>, <xref ref-type="bibr" rid="B12">12</xref>). Previous studies probed the relationship between IR and ACM in different population. An observational prospective cohort study that enrolled 15,773 patients with type 2 diabetes showed that highest IR predicts ACM in type 2 diabetes (<xref ref-type="bibr" rid="B13">13</xref>). High IR, as measured by HOMA-IR, identified postmenopausal women at higher risk for cancer-specific and ACM (<xref ref-type="bibr" rid="B14">14</xref>). In addition, A meta-analysis included seven articles involving 26,976 non-diabetic adults showed that the highest HOMA-IR increased the risk of ACM by 34% when compared with the lowest category (<xref ref-type="bibr" rid="B15">15</xref>). For elderly people, there were different conclusions. Among community-dwelling older individuals over 65 years, HOMA-IR and low-grade systemic inflammation was associated with a 9-year ACM and CVM risk (<xref ref-type="bibr" rid="B16">16</xref>). Aging and high C-reactive protein levels were, usually, risk factors for cardiovascular disease mortality. We did not evaluate systemic inflammation in our study. A community-based prospective study selected participants with age &#x02265;65 years in Korea (<xref ref-type="bibr" rid="B17">17</xref>). Elderly subjects in the fifth and first quintile of HOMA-IR values had increased rates of ACM and CVM as there is a threshold level of HOMA-IR in relation to mortality. The HOMA-IR was lower in Korea study (1st quintile &#x02264; 0.67 and 5th quintile &#x0003E; 1.50). Our work showed similar with the study in Korea; however, we used the TyG index to evaluate IR, not HOMA-IR, in elderly hypertension patients.</p>
<p>A previous study showed that there was a striking U-shaped relationship between FBG levels and in-hospital and 3-year mortality in older patients with acute myocardial infarction (AMI) (<xref ref-type="bibr" rid="B18">18</xref>). The study observed that mild to moderately low FBG levels ( &#x02264; 5 mmol/L, 90 mg/dl) were associated with a relative increase in mortality risk. Hypoglycemia and rapid changes in blood glucose level were shown to increase levels of counterregulatory hormones, such as epinephrine and norepinephrine, which may induce vasoconstriction and platelet aggregation, resulting in ischemia of cardiovascular or cerebrovascular (<xref ref-type="bibr" rid="B19">19</xref>). In the elderly population, the decrease in skeletal muscle mass is generally accompanied by weight loss. A study that recruited elderly individuals (&#x02265;65 years) in Taiwan showed that elderly subjects with sarcopenic obesity had the highest ACM (<xref ref-type="bibr" rid="B19">19</xref>). In contrast, except for the TG level, none of the other lipid profile indices were related to ACM in patients aged over 75 years (<xref ref-type="bibr" rid="B20">20</xref>). The mortality risk decreased by 17% for each 1 mmol/L increase serum level of TG in ZODIAC study (<xref ref-type="bibr" rid="B20">20</xref>). The lower TG had higher risk of ACM for elderly population. One study, which enrolled individuals aged 65 and older residing in northern Manhattan in 1992&#x02013;1994 and 1999&#x02013;2002, showed low cholesterol level was a robust predictor of mortality in the non-demented elderly and may be a surrogate of frailty or subclinical disease (<xref ref-type="bibr" rid="B21">21</xref>). Our study was collected from 1999 to 2014 in the same country as the study (<xref ref-type="bibr" rid="B21">21</xref>), so the life diet structure and level were similar. The mean TG of the patients with mortality was 155 mg/dl (<xref ref-type="bibr" rid="B21">21</xref>). Therefore, the finding of our study, specifically of the 1 SD decrease of TyG index when TyG index &#x0003C;9.45 in elderly with aged &#x02265;60 years and 19% increased risk of ACM was persuasive. Other factors, such as body composition and nutritional state, might be predictors of mortality in the elderly population (<xref ref-type="bibr" rid="B17">17</xref>). Older age, anemia, lower baseline hemoglobin level (<xref ref-type="bibr" rid="B22">22</xref>), and lower BMI had a greater effect on mortality.</p>
<p>Only when TyG index &#x02265;9.52, TyG-index showed significant with CVM. A previous study had reported that IR was associated with cardiovascular disease (<xref ref-type="bibr" rid="B23">23</xref>). The relationship between IR and endothelial dysfunction may the underlying biological mechanism of cardiovascular. This mostly includes inflammation (<xref ref-type="bibr" rid="B24">24</xref>) and functional impairment in the endothelium of blood vessels (<xref ref-type="bibr" rid="B25">25</xref>) which leads to atherosclerosis and cardiovascular disease. This simple, convenient, and low-cost TyG index was of research interest in many Countries and could be used to screen for IR in the hypertensive community. Furthermore, Park et al. (<xref ref-type="bibr" rid="B26">26</xref>) reported that TyG-index is an independent predictor of coronary artery calcium progression. We first investigate relationship between TyG index and CVM and ACM in hypertension. The Kaplan-Meier survival curve by TyG index groups also confirmed that the higher TyG index was associated with increased higher incident of ACM and CVM.</p>
<p>Our study still had several limitations that need to be mentioned. First, we did not have multiple-time monitoring of the TyG index along the follow-up, which may provide more information. Secondly, we did not compare the TyG index with HOMA-IR and the hyperinsulinemic-euglycemic clamp test. Thirdly, nutritional habits or energy intake were not recorded. Although we did not adjust for these potential confounding variables, we used other variables, such as BMI or cholesterol levels, which are indirectly related to nutritional habits or energy intake. Finally, this was a population-based study conducted among hypertension participants in the United States. Therefore, our findings may not be generalizable to other populations.</p>
</sec>
<sec sec-type="conclusions" id="s5">
<title>Conclusion</title>
<p>We first time revealed association between IR (TyG index), ACM, and CVM among patients with hypertension. We demonstrated that the association was non-linear between ACM and TyG index in elderly with aged &#x02265;60 years. But for CVM, higher TyG index had high risk among patients with hypertension only when TyG index &#x02265;9.52.</p>
</sec>
<sec sec-type="data-availability" id="s6">
<title>Data Availability Statement</title>
<p>The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/<xref ref-type="sec" rid="s11">Supplementary Material</xref>.</p>
</sec>
<sec id="s7">
<title>Ethics Statement</title>
<p>The studies involving human participants were reviewed and approved by the Institutional Review Board of the Centers for Disease Control and Prevention. The patients/participants provided their written informed consent to participate in this study.</p>
</sec>
<sec id="s8">
<title>Author Contributions</title>
<p>DZ and Y-qF contributed to the conception or design of the study and drafted the manuscript. X-cL contributed to the acquisition of data, interpretation of data, and analysis of data. Y-qH and LK contributed to the interpretation of data and critical revision of the article for important intellectual content. All authors gave final approval of the article.</p>
</sec>
<sec sec-type="funding-information" id="s9">
<title>Funding</title>
<p>This research was supported by Science and Technology Plan Program of Guangzhou (201803040012), the Key Area R&#x00026;D Program of Guangdong Province (No. 2019B020227005), Guangdong Provincial People&#x00027;s Hospital Clinical Research Fund (Y012018085), the Fundamental and Applied Basic Research Foundation Project of Guangdong Province (2020A1515010738), High-level Hospital Construction Project of Guangdong Provincial People&#x00027;s Hospital (DFJH2020022), and Guangdong Provincial Clinical Research Center for Cardiovascular Disease (2020B1111170011).</p>

</sec>
<sec sec-type="COI-statement" id="conf1">
<title>Conflict of Interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="disclaimer" id="s10">
<title>Publisher&#x00027;s Note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec> </body>
<back>
<ack><p>We gratefully acknowledge the contributions of all staffs who work on the National Health and Nutrition Examination Surveys.</p>
</ack>
<sec sec-type="supplementary-material" id="s11">
<title>Supplementary Material</title>
<p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fcvm.2021.778038/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fcvm.2021.778038/full#supplementary-material</ext-link></p>
<supplementary-material xlink:href="Data_Sheet_1.docx" id="SM1" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kjeldsen</surname> <given-names>SE</given-names></name> <name><surname>Narkiewicz</surname> <given-names>K</given-names></name> <name><surname>Burnier</surname> <given-names>M</given-names></name> <name><surname>Oparil</surname> <given-names>S</given-names></name></person-group>. <article-title>The global burden of disease study 2015 and blood pressure</article-title>. <source>Blood Press.</source> (<year>2017</year>) <volume>26</volume>:<fpage>1</fpage>. <pub-id pub-id-type="doi">10.1080/08037051.2016.1267557</pub-id><pub-id pub-id-type="pmid">27951726</pub-id></citation></ref>
<ref id="B2">
<label>2.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bromfield</surname> <given-names>S</given-names></name> <name><surname>Muntner</surname> <given-names>P</given-names></name></person-group>. <article-title>High blood pressure: the leading global burden of disease risk factor and the need for worldwide prevention programs</article-title>. <source>Curr Hypertens Rep.</source> (<year>2013</year>) <volume>15</volume>:<fpage>134</fpage>&#x02013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1007/s11906-013-0340-9</pub-id><pub-id pub-id-type="pmid">23536128</pub-id></citation></ref>
<ref id="B3">
<label>3.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>da Silva</surname> <given-names>AA</given-names></name> <name><surname>do Carmo</surname> <given-names>JM</given-names></name> <name><surname>Li</surname> <given-names>X</given-names></name> <name><surname>Wang</surname> <given-names>Z</given-names></name> <name><surname>Mouton</surname> <given-names>AJ</given-names></name> <name><surname>Hall</surname> <given-names>JE</given-names></name></person-group>. <article-title>Role of hyperinsulinemia and insulin resistance in hypertension: metabolic syndrome revisited</article-title>. <source>Can J Cardiol.</source> (<year>2020</year>) <volume>36</volume>:<fpage>671</fpage>&#x02013;<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1016/j.cjca.2020.02.066</pub-id><pub-id pub-id-type="pmid">32389340</pub-id></citation></ref>
<ref id="B4">
<label>4.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bello-Chavolla</surname> <given-names>OY</given-names></name> <name><surname>Antonio-Villa</surname> <given-names>NE</given-names></name> <name><surname>Vargas-V&#x000E1;zquez</surname> <given-names>A</given-names></name> <name><surname>Martag&#x000F3;n</surname> <given-names>AJ</given-names></name> <name><surname>Mehta</surname> <given-names>R</given-names></name> <name><surname>Arellano-Campos</surname> <given-names>O</given-names></name> <etal/></person-group>. <article-title>Prediction of incident hypertension and arterial stiffness using the non-insulin-based metabolic score for insulin resistance (METS-IR) index</article-title>. <source>J Clin Hypertens.</source> (<year>2019</year>) <volume>21</volume>:<fpage>1063</fpage>&#x02013;<lpage>70</lpage>. <pub-id pub-id-type="doi">10.1111/jch.13614</pub-id><pub-id pub-id-type="pmid">31318156</pub-id></citation></ref>
<ref id="B5">
<label>5.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bamaiyi</surname> <given-names>AJ</given-names></name> <name><surname>Woodiwiss</surname> <given-names>AJ</given-names></name></person-group>. <article-title>Insulin resistance influences the impact of hypertension on left ventricular diastolic dysfunction in a community sample</article-title>. <source>Clin Cardiol.</source> (<year>2019</year>) <volume>42</volume>:<fpage>305</fpage>&#x02013;<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1002/clc.23145</pub-id><pub-id pub-id-type="pmid">30592058</pub-id></citation></ref>
<ref id="B6">
<label>6.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Minh</surname> <given-names>HV</given-names></name> <name><surname>Tien</surname> <given-names>HA</given-names></name> <name><surname>Sinh</surname> <given-names>CT</given-names></name> <name><surname>Thang</surname> <given-names>DC</given-names></name> <name><surname>Chen</surname> <given-names>CH</given-names></name></person-group>. <article-title>Assessment of preferred methods to measure insulin resistance in Asian patients with hypertension</article-title>. <source>J Clin Hypertension.</source> (<year>2021</year>) <volume>23</volume>:<fpage>529</fpage>&#x02013;<lpage>37</lpage>. <pub-id pub-id-type="doi">10.1111/jch.14155</pub-id><pub-id pub-id-type="pmid">33415834</pub-id></citation></ref>
<ref id="B7">
<label>7.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chobanian</surname> <given-names>AV</given-names></name> <name><surname>Bakris</surname> <given-names>GL</given-names></name> <name><surname>Black</surname> <given-names>HR</given-names></name> <name><surname>Cushman</surname> <given-names>WC</given-names></name> <name><surname>Green</surname> <given-names>LA</given-names></name> <name><surname>Izzo JL</surname> <given-names>Jr</given-names></name></person-group>., et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. <source>JAMA.</source> (<year>2003</year>) <volume>289</volume>:<fpage>2560</fpage>&#x02013;<lpage>72</lpage>. <pub-id pub-id-type="doi">10.1001/jama.289.19.2560</pub-id><pub-id pub-id-type="pmid">12748199</pub-id></citation></ref>
<ref id="B8">
<label>8.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>American</surname> <given-names>Diabetes Association</given-names></name></person-group>. <article-title>Standards of medical care for patients with diabetes mellitus</article-title>. <source>Diab Care</source>. (<year>2003</year>) 26 Suppl <volume>1</volume>:<fpage>S33</fpage>&#x02013;<lpage>50</lpage>. <pub-id pub-id-type="doi">10.2337/diacare.26.2007.S33</pub-id><pub-id pub-id-type="pmid">12502618</pub-id></citation></ref>
<ref id="B9">
<label>9.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Simental-Mend&#x000ED;a</surname> <given-names>LE</given-names></name> <name><surname>Rodr&#x000ED;guez-Mor&#x000E1;n</surname> <given-names>M</given-names></name> <name><surname>Guerrero-Romero</surname> <given-names>F</given-names></name></person-group>. <article-title>The product of fasting glucose and triglycerides as surrogate for identifying insulin resistance in apparently healthy subjects</article-title>. <source>Metab Syndr Relat Disord.</source> (<year>2008</year>) <volume>6</volume>:<fpage>299</fpage>&#x02013;<lpage>304</lpage>. <pub-id pub-id-type="doi">10.1089/met.2008.0034</pub-id><pub-id pub-id-type="pmid">19067533</pub-id></citation></ref>
<ref id="B10">
<label>10.</label>
<citation citation-type="book"><person-group person-group-type="author"><name><surname>Levey</surname> <given-names>AS</given-names></name> <name><surname>Coresh</surname> <given-names>J</given-names></name> <name><surname>Bolton</surname> <given-names>K</given-names></name> <name><surname>Culleton</surname> <given-names>B</given-names></name> <name><surname>Harvey</surname> <given-names>KS</given-names></name> <name><surname>Ikizler</surname> <given-names>TA</given-names></name> <etal/></person-group>. <article-title>K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification</article-title>. <source>Am J Kidney Dis.</source> (<year>2002</year>) 39(2 Suppl 1):S1-266.<pub-id pub-id-type="pmid">11904577</pub-id></citation></ref>
<ref id="B11">
<label>11.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Khan</surname> <given-names>SH</given-names></name> <name><surname>Sobia</surname> <given-names>F</given-names></name> <name><surname>Niazi</surname> <given-names>NK</given-names></name> <name><surname>Manzoor</surname> <given-names>SM</given-names></name> <name><surname>Fazal</surname> <given-names>N</given-names></name> <name><surname>Ahmad</surname> <given-names>F</given-names></name></person-group>. <article-title>Metabolic clustering of risk factors: evaluation of triglyceride-glucose index (TyG index) for evaluation of insulin resistance</article-title>. <source>Diabetol Metab Syndr.</source> (<year>2018</year>) <volume>10</volume>:<fpage>74</fpage>. <pub-id pub-id-type="doi">10.1186/s13098-018-0376-8</pub-id><pub-id pub-id-type="pmid">30323862</pub-id></citation></ref>
<ref id="B12">
<label>12.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Guerrero-Romero</surname> <given-names>F</given-names></name> <name><surname>Simental-Mend&#x000ED;a</surname> <given-names>LE</given-names></name> <name><surname>Gonz&#x000E1;lez-Ortiz</surname> <given-names>M</given-names></name> <name><surname>Mart&#x000ED;nez-Abundis</surname> <given-names>E</given-names></name> <name><surname>Ramos-Zavala</surname> <given-names>MG</given-names></name> <name><surname>Hern&#x000E1;ndez-Gonz&#x000E1;lez</surname> <given-names>SO</given-names></name> <etal/></person-group>. <article-title>The product of triglycerides and glucose, a simple measure of insulin sensitivity. Comparison with the euglycemic-hyperinsulinemic clamp</article-title>. <source>J Clin Endocrinol Metab.</source> (<year>2010</year>) <volume>95</volume>:<fpage>3347</fpage>&#x02013;<lpage>51</lpage>. <pub-id pub-id-type="doi">10.1210/jc.2010-0288</pub-id><pub-id pub-id-type="pmid">20484475</pub-id></citation></ref>
<ref id="B13">
<label>13.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Penno</surname> <given-names>G</given-names></name> <name><surname>Solini</surname> <given-names>A</given-names></name> <name><surname>Orsi</surname> <given-names>E</given-names></name> <name><surname>Bonora</surname> <given-names>E</given-names></name> <name><surname>Fondelli</surname> <given-names>C</given-names></name> <name><surname>Trevisan</surname> <given-names>R</given-names></name></person-group>. <article-title>et al. Insulin resistance, diabetic kidney disease, and all-cause mortality in individuals with type 2 diabetes: a prospective cohort study</article-title>. <source>BMC Med.</source> (<year>2021</year>) <volume>19</volume>:<fpage>66</fpage>. <pub-id pub-id-type="doi">10.1186/s12916-021-01936-3</pub-id><pub-id pub-id-type="pmid">33715620</pub-id></citation></ref>
<ref id="B14">
<label>14.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pan</surname> <given-names>K</given-names></name> <name><surname>Nelson</surname> <given-names>RA</given-names></name> <name><surname>Wactawski-Wende</surname> <given-names>J</given-names></name> <name><surname>Lee</surname> <given-names>DJ</given-names></name> <name><surname>Manson</surname> <given-names>JE</given-names></name> <name><surname>Aragaki</surname> <given-names>AK</given-names></name> <etal/></person-group>. <article-title>Insulin resistance and cancer-specific and all-cause mortality in postmenopausal women: the women&#x00027;s health initiative</article-title>. <source>J Natl Cancer Inst.</source> (<year>2020</year>) <volume>112</volume>:<fpage>170</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1093/jnci/djz069</pub-id><pub-id pub-id-type="pmid">31184362</pub-id></citation></ref>
<ref id="B15">
<label>15.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname> <given-names>X</given-names></name> <name><surname>Li</surname> <given-names>J</given-names></name> <name><surname>Zheng</surname> <given-names>S</given-names></name> <name><surname>Luo</surname> <given-names>Q</given-names></name> <name><surname>Zhou</surname> <given-names>C</given-names></name> <name><surname>Wang</surname> <given-names>C</given-names></name></person-group>. <article-title>Fasting insulin, insulin resistance, and risk of cardiovascular or all-cause mortality in non-diabetic adults: a meta-analysis</article-title>. <source>Biosci. Rep.</source> (<year>2017</year>) <volume>37</volume>:<fpage>BSR20170947</fpage>. <pub-id pub-id-type="doi">10.1042/BSR20170947</pub-id><pub-id pub-id-type="pmid">28811358</pub-id></citation></ref>
<ref id="B16">
<label>16.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zuliani</surname> <given-names>G</given-names></name> <name><surname>Morieri</surname> <given-names>ML</given-names></name> <name><surname>Volpato</surname> <given-names>S</given-names></name> <name><surname>Maggio</surname> <given-names>M</given-names></name> <name><surname>Cherubini</surname> <given-names>A</given-names></name> <name><surname>Francesconi</surname> <given-names>D</given-names></name> <etal/></person-group>. <article-title>Insulin resistance and systemic inflammation, but not metabolic syndrome phenotype, predict 9 years mortality in older adults</article-title>. <source>Atherosclerosis.</source> (<year>2014</year>) <volume>235</volume>:<fpage>538</fpage>&#x02013;<lpage>45</lpage>. <pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2014.05.959</pub-id><pub-id pub-id-type="pmid">24956526</pub-id></citation></ref>
<ref id="B17">
<label>17.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kim HJ Ryu</surname> <given-names>J</given-names></name> <name><surname>Ahn</surname> <given-names>SY</given-names></name> <name><surname>Kim</surname> <given-names>S</given-names></name> <name><surname>Lim</surname> <given-names>S</given-names></name> <name><surname>Na</surname> <given-names>KY</given-names></name> <etal/></person-group>. <article-title>Association of insulin resistance with lower glomerular filtration rate and all-cause mortality in the Korean elderly population: a community-based prospective cohort study</article-title>. <source>Tohoku J Exp Med.</source> (<year>2013</year>) <volume>231</volume>:<fpage>271</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1620/tjem.231.271</pub-id><pub-id pub-id-type="pmid">24292690</pub-id></citation></ref>
<ref id="B18">
<label>18.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname> <given-names>SW</given-names></name> <name><surname>Zhou</surname> <given-names>YJ</given-names></name> <name><surname>Nie</surname> <given-names>XM</given-names></name> <name><surname>Liu</surname> <given-names>YY</given-names></name> <name><surname>Du</surname> <given-names>J</given-names></name> <name><surname>Hu</surname> <given-names>DY</given-names></name> <etal/></person-group>. <article-title>Effect of abnormal fasting plasma glucose level on all-cause mortality in older patients with acute myocardial infarction: results from the Beijing Elderly Acute Myocardial Infarction Study (BEAMIS)</article-title>. <source>Mayo Clin Proc.</source> (<year>2011</year>) <volume>86</volume>:<fpage>94</fpage>&#x02013;<lpage>104</lpage>. <pub-id pub-id-type="doi">10.4065/mcp.2010.0473</pub-id><pub-id pub-id-type="pmid">21282483</pub-id></citation></ref>
<ref id="B19">
<label>19.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Galassetti</surname> <given-names>P</given-names></name> <name><surname>Davis</surname> <given-names>SN</given-names></name></person-group>. <article-title>Effects of insulin per se on neuroendocrine and metabolic counter-regulatory responses to hypoglycaemia</article-title>. <source>Clin Sci</source>. (<year>2000</year>) <volume>99</volume>:<fpage>351</fpage>&#x02013;<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1042/cs0990351</pub-id><pub-id pub-id-type="pmid">11052915</pub-id></citation></ref>
<ref id="B20">
<label>20.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>van Hateren</surname> <given-names>KJ</given-names></name> <name><surname>Landman</surname> <given-names>GW</given-names></name> <name><surname>Kleefstra</surname> <given-names>N</given-names></name> <name><surname>Logtenberg</surname> <given-names>SJ</given-names></name> <name><surname>Groenier</surname> <given-names>KH</given-names></name> <name><surname>Kamper</surname> <given-names>AM</given-names></name> <etal/></person-group>. <article-title>The lipid profile and mortality risk in elderly type 2 diabetic patients: a ten-year follow-up study (ZODIAC-13)</article-title>. <source>PLoS ONE.</source> (<year>2009</year>) <volume>4</volume>:<fpage>e8464</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0008464</pub-id><pub-id pub-id-type="pmid">20041116</pub-id></citation></ref>
<ref id="B21">
<label>21.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schupf</surname> <given-names>N</given-names></name> <name><surname>Costa</surname> <given-names>R</given-names></name> <name><surname>Luchsinger</surname> <given-names>J</given-names></name> <name><surname>Tang</surname> <given-names>MX</given-names></name> <name><surname>Lee</surname> <given-names>JH</given-names></name> <name><surname>Mayeux</surname> <given-names>R</given-names></name></person-group>. <article-title>Relationship between plasma lipids and all-cause mortality in nondemented elderly</article-title>. <source>J Am Geriatr Soc.</source> (<year>2005</year>) <volume>53</volume>:<fpage>219</fpage>&#x02013;<lpage>26</lpage>. <pub-id pub-id-type="doi">10.1111/j.1532-5415.2005.53106.x</pub-id><pub-id pub-id-type="pmid">15673344</pub-id></citation></ref>
<ref id="B22">
<label>22.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zakai</surname> <given-names>NA</given-names></name> <name><surname>French</surname> <given-names>B</given-names></name> <name><surname>Arnold</surname> <given-names>AM</given-names></name> <name><surname>Newman</surname> <given-names>AB</given-names></name> <name><surname>Fried</surname> <given-names>LF</given-names></name> <name><surname>Robbins</surname> <given-names>J</given-names></name> <etal/></person-group>. <article-title>Hemoglobin decline, function, and mortality in the elderly: the cardiovascular health study</article-title>. <source>Am J Hematol.</source> (<year>2013</year>) <volume>88</volume>:<fpage>5</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1002/ajh.23336</pub-id><pub-id pub-id-type="pmid">23044913</pub-id></citation></ref>
<ref id="B23">
<label>23.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Salazar</surname> <given-names>MR</given-names></name> <name><surname>Carbajal</surname> <given-names>HA</given-names></name> <name><surname>Espeche</surname> <given-names>WG</given-names></name> <name><surname>Aizpur&#x000FA;a</surname> <given-names>M</given-names></name> <name><surname>Dulbecco</surname> <given-names>CA</given-names></name> <name><surname>Reaven</surname> <given-names>GM</given-names></name></person-group>. <article-title>Comparison of two surrogate estimates of insulin resistance to predict cardiovascular disease in apparently healthy individuals</article-title>. <source>Nutr Metab Cardiovasc Dis.</source> [2017] <volume>27</volume>:<fpage>366</fpage>&#x02013;<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1016/j.numecd.2016.12.002</pub-id><pub-id pub-id-type="pmid">28254109</pub-id></citation></ref>
<ref id="B24">
<label>24.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname> <given-names>DY</given-names></name> <name><surname>Rhee</surname> <given-names>EJ</given-names></name> <name><surname>Chang</surname> <given-names>Y</given-names></name> <name><surname>Sohn</surname> <given-names>CI</given-names></name> <name><surname>Shin HC Ryu</surname> <given-names>S</given-names></name> <etal/></person-group>. <article-title>Impact of systemic inflammation on the relationship between insulin resistance and all-cause and cancer-related mortality</article-title>. <source>Postgrad Med.</source> (<year>2018</year>) <volume>81</volume>:<fpage>52</fpage>&#x02013;<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1016/j.metabol.2017.11.014</pub-id><pub-id pub-id-type="pmid">29191456</pub-id></citation></ref>
<ref id="B25">
<label>25.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ormazabal</surname> <given-names>V</given-names></name> <name><surname>Nair</surname> <given-names>S</given-names></name> <name><surname>Elfeky</surname> <given-names>O</given-names></name> <name><surname>Aguayo</surname> <given-names>C</given-names></name> <name><surname>Salomon</surname> <given-names>C</given-names></name></person-group>. <article-title>Association between insulin resistance and the development of cardiovascular disease</article-title>. <source>Cardiovasc Diabetol.</source> (<year>2018</year>) <volume>17</volume>:<fpage>122</fpage>. <pub-id pub-id-type="doi">10.1186/s12933-018-0762-4</pub-id><pub-id pub-id-type="pmid">30170598</pub-id></citation></ref>
<ref id="B26">
<label>26.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Park</surname> <given-names>K</given-names></name> <name><surname>Ahn</surname> <given-names>CW</given-names></name> <name><surname>Lee</surname> <given-names>SB</given-names></name> <name><surname>Kang</surname> <given-names>S</given-names></name></person-group>. <article-title>Elevated TyG index predicts progression of coronary artery calcification</article-title>. <source>Diab Care.</source> (<year>2019</year>) <volume>42</volume>:<fpage>1569</fpage>&#x02013;<lpage>73</lpage>. <pub-id pub-id-type="doi">10.2337/dc18-1920</pub-id><pub-id pub-id-type="pmid">31182490</pub-id></citation></ref>
</ref-list>
<glossary>
<def-list>
<title>Abbreviations</title>
<def-item><term>IR</term>
<def><p>insulin resistance</p></def></def-item>
<def-item><term>CVM</term>
<def><p>cardiovascular mortality</p></def></def-item>
<def-item><term>ACM</term>
<def><p>all-cause mortality</p></def></def-item>
<def-item><term>TyG index</term>
<def><p>triglyceride glycemic index</p></def></def-item>
<def-item><term>HOMA-IR</term>
<def><p>homeostatic model assessment IR</p></def></def-item>
<def-item><term>SBP</term>
<def><p>systolic blood pressure</p></def></def-item>
<def-item><term>DBP</term>
<def><p>diastolic blood pressure</p></def></def-item>
<def-item><term>TC</term>
<def><p>total cholesterol</p></def></def-item>
<def-item><term>TG</term>
<def><p>triglyceride</p></def></def-item>
<def-item><term>LDL-C</term>
<def><p>low-density lipoprotein cholesterol</p></def></def-item>
<def-item><term>HDL-C</term>
<def><p>high-density lipoprotein cholesterol</p></def></def-item>
<def-item><term>FBG</term>
<def><p>fasting blood glucose</p></def></def-item>
<def-item><term>eGFR</term>
<def><p>estimated glomerular filtration rate</p></def></def-item>
<def-item><term>BMI</term>
<def><p>body mass index</p></def></def-item>
<def-item><term>HbA1C</term>
<def><p>hemoglobin A1c.</p></def></def-item>
</def-list>
</glossary> 
</back>
</article> 